Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Borbath, I.; Clarke, S. J.; Hitre, E.; Louvet, C.; Macarulla, T.; Oh, D. Y.; Spratlin, J. L.; Valle, J. W.; Weiss, K. H.; Berman, C.; Howland, M.; Ye, Y.; Cho, T.; Moran, S.; Javle, M. M. |
| Abstract Title: | Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz247.158 |
| Language: | English |
| ACCESSION: | WOS:000491295502259 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz247.158 |
| Notes: | Meeting Abstract: 832TiP -- Appears on pages v319-v320 of the abstract book -- Source: Wos |
